Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis
Journal of Cardiac Failure · 2024-08 · 30 (8) · 973-980
DOI: 10.1016/j.cardfail.2023.11.016 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Cardiac Failure, 2024-08. Verfasst von Ahmad Masri und 16 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health & Science University, Portland, Oregon. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: AstraZeneca, Ionis Pharmaceuticals.
Abstract (Originalsprache)
BACKGROUND: Hereditary transthyretin amyloidosis (ATTRv) is associated with polyneuropathy, cardiomyopathy, or both. The effects of eplontersen on cardiac structure and function were assessed. METHODS AND RESULTS: NEURO-TTRansform was an open-label trial involving 144 adults with ATTRv polyneuropathy (49 patients [34%] with cardiomyopathy) receiving eplontersen throughout and compared with a historical placebo group (n = 60; 30 patients [50%] with cardiomyopathy) from the NEURO-TTR trial at week 65. Treatment effect (eplontersen vs placebo), presented as mean difference (95% confidence interval) was analyzed after adjusting for age, sex, region, baseline value, ATTRv disease stage, previous ATTRv treatment, and V30M transthyretin variant. There were notable differences at baseline between the eplontersen group and historical placebo. In the cardiomyopathy subgroup, 65 weeks of eplontersen treatment was associated with improvement from baseline relative to placebo in left ventricular ejection fraction of 4.3% (95% confidence interval 1.40-21.01; P = .049) and stroke volume 10.64 mL (95% confidence interval 3.99-17.29; P = .002) while the remainder of echocardiographic parameters remained stable. CONCLUSIONS: Eplontersen was associated with stable or improved measures of cardiac structure and function vs historical placebo in patients with ATTRv polyneuropathy and cardiomyopathy. Further investigation into eplontersen's effect on transthyretin amyloid cardiomyopathy is being conducted in the CARDIO-TTRansform trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oregon Health & Science University, Portland, Oregon.
- Columbia University Irving Medical Center, New York, New York.
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
- Centro Hospitalar Universitário Lisboa-Norte, Hospital de Santa Maria, Lisbon, Portugal.
- Amyloidosis Center and Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.
Förderung
- AstraZeneca
- Ionis Pharmaceuticals
Zitieren
APA
Masri, A., Maurer, M. S., Claggett, B. L., Kulac, I., Waddington Cruz, M., Conceição, I., Weiler, M., Berk, J. L., Gertz, M., Gillmore, J. D., Rush, S., Chen, J., Zhou, W., Kwoh, J., Duran, J. M., Tsimikas, S., & Solomon, S. D. (2024). Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. Journal of Cardiac Failure, 30(8), 973-980. https://doi.org/10.1016/j.cardfail.2023.11.016
Vancouver
Masri A, Maurer MS, Claggett BL, Kulac I, Waddington Cruz M, Conceição I, et al. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. Journal of Cardiac Failure. 2024;30(8):973-980. doi:10.1016/j.cardfail.2023.11.016
BibTeX
@article{Masri2024,
author = {Masri, Ahmad and Maurer, Mathew S and Claggett, Brian L and Kulac, Ian and Waddington Cruz, Marcia and Conceição, Isabel and Weiler, Markus and Berk, John L and Gertz, Morie and Gillmore, Julian D and Rush, Stephen and Chen, Jersey and Zhou, Wunan and Kwoh, Jesse and Duran, Jason M and Tsimikas, Sotirios and Solomon, Scott D},
title = {Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis},
journal = {Journal of Cardiac Failure},
year = {2024},
volume = {30},
number = {8},
pages = {973--980},
doi = {10.1016/j.cardfail.2023.11.016}
}
EUVIMED